S&P 500   2,488.65 (-1.51%)
DOW   21,052.53 (-1.69%)
QQQ   183.37 (-1.42%)
AAPL   241.41 (-1.44%)
FB   154.18 (-2.53%)
MSFT   153.90 (-0.88%)
GOOGL   1,092.70 (-2.18%)
AMZN   1,906.59 (-0.64%)
CGC   13.25 (-3.99%)
NVDA   243.91 (-4.52%)
BABA   187.11 (-0.95%)
MU   41.22 (+0.32%)
GE   6.73 (-2.46%)
TSLA   480.01 (+5.62%)
AMD   42.59 (-4.27%)
T   27.46 (-4.52%)
ACB   0.81 (-2.41%)
F   4.24 (-2.75%)
NFLX   361.76 (-2.25%)
BAC   20.03 (-2.63%)
GILD   78.21 (+1.60%)
DIS   93.88 (-3.19%)
PRI   80.69 (-2.50%)
S&P 500   2,488.65 (-1.51%)
DOW   21,052.53 (-1.69%)
QQQ   183.37 (-1.42%)
AAPL   241.41 (-1.44%)
FB   154.18 (-2.53%)
MSFT   153.90 (-0.88%)
GOOGL   1,092.70 (-2.18%)
AMZN   1,906.59 (-0.64%)
CGC   13.25 (-3.99%)
NVDA   243.91 (-4.52%)
BABA   187.11 (-0.95%)
MU   41.22 (+0.32%)
GE   6.73 (-2.46%)
TSLA   480.01 (+5.62%)
AMD   42.59 (-4.27%)
T   27.46 (-4.52%)
ACB   0.81 (-2.41%)
F   4.24 (-2.75%)
NFLX   361.76 (-2.25%)
BAC   20.03 (-2.63%)
GILD   78.21 (+1.60%)
DIS   93.88 (-3.19%)
PRI   80.69 (-2.50%)
S&P 500   2,488.65 (-1.51%)
DOW   21,052.53 (-1.69%)
QQQ   183.37 (-1.42%)
AAPL   241.41 (-1.44%)
FB   154.18 (-2.53%)
MSFT   153.90 (-0.88%)
GOOGL   1,092.70 (-2.18%)
AMZN   1,906.59 (-0.64%)
CGC   13.25 (-3.99%)
NVDA   243.91 (-4.52%)
BABA   187.11 (-0.95%)
MU   41.22 (+0.32%)
GE   6.73 (-2.46%)
TSLA   480.01 (+5.62%)
AMD   42.59 (-4.27%)
T   27.46 (-4.52%)
ACB   0.81 (-2.41%)
F   4.24 (-2.75%)
NFLX   361.76 (-2.25%)
BAC   20.03 (-2.63%)
GILD   78.21 (+1.60%)
DIS   93.88 (-3.19%)
PRI   80.69 (-2.50%)
S&P 500   2,488.65 (-1.51%)
DOW   21,052.53 (-1.69%)
QQQ   183.37 (-1.42%)
AAPL   241.41 (-1.44%)
FB   154.18 (-2.53%)
MSFT   153.90 (-0.88%)
GOOGL   1,092.70 (-2.18%)
AMZN   1,906.59 (-0.64%)
CGC   13.25 (-3.99%)
NVDA   243.91 (-4.52%)
BABA   187.11 (-0.95%)
MU   41.22 (+0.32%)
GE   6.73 (-2.46%)
TSLA   480.01 (+5.62%)
AMD   42.59 (-4.27%)
T   27.46 (-4.52%)
ACB   0.81 (-2.41%)
F   4.24 (-2.75%)
NFLX   361.76 (-2.25%)
BAC   20.03 (-2.63%)
GILD   78.21 (+1.60%)
DIS   93.88 (-3.19%)
PRI   80.69 (-2.50%)
Log in

NASDAQ:BMRABiomerica Stock Price, Forecast & News

$6.60
-0.47 (-6.65 %)
(As of 04/3/2020 04:00 PM ET)
Add
Compare
Today's Range
$6.30
Now: $6.60
$7.23
50-Day Range
$2.37
MA: $4.37
$16.00
52-Week Range
$2.05
Now: $6.60
$23.39
Volume1.06 million shs
Average Volume1.29 million shs
Market Capitalization$65.27 million
P/E RatioN/A
Dividend YieldN/A
Beta-0.9
Biomerica, Inc., together with its subsidiaries, develops, manufactures, and markets medical diagnostic products for the early detection and monitoring of chronic diseases and medical conditions. The company's diagnostic test kits are used to analyze blood, urine, or fecal samples from patients in the diagnosis of various diseases and other medical complications; or to measure the level of specific hormones, antibodies, antigens, or other substances, which exist in the human body in extremely small concentrations. It primarily offers its products for gastrointestinal diseases, food intolerances, diabetes, and various esoteric tests at the point-of-care and in-hospital/clinical laboratories worldwide. The company is also developing InFoods, an irritable bowel syndrome (IBS) therapy technology and diagnostic-guided therapy, which is in clinical studies to identify specific foods that when removed from the patient's diet can alleviate the patient's IBS symptoms. Biomerica, Inc. was founded in 1971 and is headquartered in Irvine, California.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 1.5Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.80 out of 5 stars


Industry, Sector and Symbol

Industry Dental equipment & supplies
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:BMRA
CUSIPN/A
Phone949-645-2111

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$5.20 million
Book Value$0.41 per share

Profitability

Net Income$-2,390,000.00

Miscellaneous

Employees54
Market Cap$65.27 million
Next Earnings Date4/20/2020 (Estimated)
OptionableNot Optionable

Receive BMRA News and Ratings via Email

Sign-up to receive the latest news and ratings for BMRA and its competitors with MarketBeat's FREE daily newsletter.


Biomerica (NASDAQ:BMRA) Frequently Asked Questions

How has Biomerica's stock been impacted by COVID-19 (Coronavirus)?

Biomerica's stock was trading at $2.90 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, BMRA shares have increased by 127.6% and is now trading at $6.60. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Biomerica?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Biomerica in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Biomerica.

When is Biomerica's next earnings date?

Biomerica is scheduled to release its next quarterly earnings announcement on Monday, April 20th 2020. View our earnings forecast for Biomerica.

How were Biomerica's earnings last quarter?

Biomerica, Inc. (NASDAQ:BMRA) released its earnings results on Wednesday, January, 15th. The company reported ($0.05) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.08) by $0.03. The company earned $1.60 million during the quarter, compared to analysts' expectations of $1.69 million. Biomerica had a negative net margin of 47.06% and a negative return on equity of 65.75%. View Biomerica's earnings history.

What price target have analysts set for BMRA?

1 Wall Street analysts have issued 1 year target prices for Biomerica's stock. Their forecasts range from $6.30 to $6.30. On average, they expect Biomerica's stock price to reach $6.30 in the next twelve months. This suggests that the stock has a possible downside of 4.5%. View analysts' price targets for Biomerica.

Has Biomerica been receiving favorable news coverage?

Media headlines about BMRA stock have been trending very negative on Friday, InfoTrie Sentiment Analysis reports. The research group identifies negative and positive media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Biomerica earned a news sentiment score of -3.3 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the next several days. View the latest news aboutBiomerica.

Are investors shorting Biomerica?

Biomerica saw a increase in short interest during the month of March. As of March 13th, there was short interest totaling 2,700 shares, an increase of 22.7% from the February 27th total of 2,200 shares. Based on an average daily trading volume, of 43,700 shares, the short-interest ratio is presently 0.1 days. Approximately 0.0% of the company's stock are short sold. View Biomerica's Current Options Chain.

Who are some of Biomerica's key competitors?

What other stocks do shareholders of Biomerica own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Biomerica investors own include Accenture (ACN), Corbus Pharmaceuticals (CRBP), General Motors (GM), Agenus (AGEN), Akers Biosciences (AKER), T2 Biosystems (TTOO), AbbVie (ABBV), Eastman Chemical (EMN), Ford Motor (F) and Kohl's (KSS).

Who are Biomerica's key executives?

Biomerica's management team includes the following people:
  • Mr. Zackary S. Irani, Chairman & CEO (Age 53)
  • Ms. Janet Moore, CFO, Treasurer, Sec. & Director (Age 68)

What is Biomerica's stock symbol?

Biomerica trades on the NASDAQ under the ticker symbol "BMRA."

How do I buy shares of Biomerica?

Shares of BMRA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Biomerica's stock price today?

One share of BMRA stock can currently be purchased for approximately $6.60.

How big of a company is Biomerica?

Biomerica has a market capitalization of $65.27 million and generates $5.20 million in revenue each year. The company earns $-2,390,000.00 in net income (profit) each year or ($0.26) on an earnings per share basis. Biomerica employs 54 workers across the globe. View additional information about Biomerica.

What is Biomerica's official website?

The official website for Biomerica is http://www.biomerica.com/.

How can I contact Biomerica?

Biomerica's mailing address is 17571 Von Karman Avenue, Irvine CA, 92614. The company can be reached via phone at 949-645-2111.

This page was last updated on 4/3/2020 by MarketBeat.com Staff

Featured Article: Earnings Reports

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel